Matthew Ku

Feasibility of an online cognitive rehabilitation programme in patients with a haematological malignancy undergoing autologous stem cell transplantation

Matthew Ku, Priscilla Gates, Steffi Renehan

Journal article  |  2021  |  INTERNAL MEDICINE JOURNAL

BACKGROUND: Chemotherapy-related cognitive impairment (CRCI) is a known adverse event that can impact cancer survivors, resulting ..

Diffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance.

J Wight, N Hamad, BA Campbell, M Ku, K Lee, H Rose, T Armytage, M Latimer, HP Lee, ST Lee, M Dickinson, R Khor, E Verner

Journal article  |  2021  |  Intern Med J

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Though agg..

Poster: ABCL-346: Overall Survival with Tafasitamab Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study

Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, Eva E Waltl, Mark Winderlich, Sumeet Ambarkhane, Georg Hess, Gilles Salles

Journal article  |  2021  |  Clinical Lymphoma Myeloma and Leukemia

Overall Survival with Tafasitamab plus Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study

Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, Eva E Waltl, Mark Winderlich, Sumeet Ambarkhane, Georg Hess, Gilles Salles

Conference Proceedings  |  2021  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

ABCL-346: Overall Survival with Tafasitamab Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study

Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, Eva E Waltl, Mark Winderlich, Sumeet Ambarkhane, Georg Hess, Gilles Salles

Journal article  |  2021  |  Clinical Lymphoma Myeloma and Leukemia

Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.

Rene-Olivier Casasnovas, George Follows, Josee M Zijlstra, Joost SP Vermaat, Nagesh Kalakonda, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger, Paolo F Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan-Manuel Sancho, Michael Schuster, et al.

Journal article  |  2021  |  Clin Lymphoma Myeloma Leuk

BACKGROUND: The SADAL study evaluated oral selinexor in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DL..

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Marie Maerevoet, Josee M Zijlstra, George Follows, Rene-Olivier Casasnovas, JSP Vermaat, Nagesh Kalakonda, Andre Goy, Sylvain Choquet, Eric Van den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger, Paolo Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, et al.

Journal article  |  2021  |  JOURNAL OF HEMATOLOGY & ONCOLOGY

Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS)..

A PHASE III TRIAL OF GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GEMOX) VS RITUXIMAB PLUS GEMOX FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

M Hertzberg, M Ku, O Catalani, B Althaus, S Simko, GP Gregory

Journal article  |  2021  |  Hematological Oncology

A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Mark Hertzberg, Matthew Ku, Olivier Catalani, Betsy Althaus, Stephen Simko, Gareth P Gregory

Journal article  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

TPS7575 Background: Prognosis is poor for patients with R/R DLBCL, particularly those who are ineligible for autologous stem cell..

COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement

Georgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, Nicole Gilroy, Raina MacIntyre, Benjamin Teh, Robert Weinkove, Jennifer Curnow, Jeff Szer, Anoop K Enjeti, David M Ross, Stephen Mulligan, Judith Trotman, Michael Dickinson, Hang Quach, Phillip Choi, Mark N Polizzotto, Constantine S Tam, P Joy Ho, Matthew Ku, et al.

Journal article  |  2021  |  INTERNAL MEDICINE JOURNAL

Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vacci..